Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23946046 | 0.92 | GBA1 (0.33) | GBA1 | |
| SCHEMBL25928048 | 0.92 | GBA1 (0.33) | GBA1 | |
| SCHEMBL22856348 | 0.87 | GBA1 (0.37) | ALDH1A1GBA1SIGMAR1 | |
| SCHEMBL24608218 | 0.86 | GBA1 (0.34) | GBA1 | |
| SCHEMBL25469108 | 0.86 | GBA1 (0.38) | ALDH1A1GBA1 | |
| SCHEMBL23945304 | 0.85 | PIK3CD (0.46) | ALDH1A1SIGMAR1 | |
| SCHEMBL23945856 | 0.82 | PIK3CD (0.38) | ALDH1A1GBA1 | |
| SCHEMBL23695847 | 0.82 | PIK3CD (0.38) | ALDH1A1GBA1 | |
| SCHEMBL23602362 | 0.81 | PIK3CD (0.37) | ALDH1A1GBA1 | |
| SCHEMBL24673551 | 0.81 | PIK3CD (0.37) | ALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885GBA1 1887/4885SIGMAR1 2983/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885GBA1 3212/4885SIGMAR1 3199/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885GBA1 3212/4885SIGMAR1 3199/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885GBA1 1887/4885SIGMAR1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.